PD-L1 expression associates with favorable survival of patients with cancer of unknown primary (CUP) not treated with checkpoint inhibitors.

Tanja Abu SabbahSarah TheurerHideo Andreas BabaSmiths LueongJassin Rashidi-AlavijehThomas HilserYasmin ZaunMartin MetzenmacherMichael PogorzelskiIsabel VirchowIna PretzellKarina KostbadeJürgen TreckmannMarcel WieswegMartin SchulerStefan KasperGregor Zaun

Published in: European journal of cancer (Oxford, England : 1990) (2024)

PD-L1 expression associates with favorable survival in checkpoint inhibitor-naïve CUP patients. This implies a role of cancer immunity in CUP biology and may nominate PD-L1 for patient stratification in further studies and clinical care.

Keyphrases

dna damage
end stage renal disease
newly diagnosed
cell cycle
healthcare
chronic kidney disease
palliative care
peritoneal dialysis
prognostic factors
papillary thyroid
case report
free survival
oxidative stress
cell proliferation
squamous cell
chronic pain
patient reported
childhood cancer